nanotech-investing Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
nanotech-investing Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
nanotech-investing Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
nanotech-investing Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
nanotech-investing Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
nanotech-investing Silo Pharma Acquires ResearchCoin Crypto Tokens in Support of Decentralized Science
nanotech-investing Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
nanotech-investing Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
nanotech-investing Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
nanotech-investing Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
nanotech-investing Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
nanotech-investing Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
nanotech-investing Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
nanotech-investing Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
nanotech-investing Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505 Pathway
Jura Announces Dismissal in Full of PEL's Appeal against certain reliefs granted in the Settlement Agreement Arbitral Award
American Pacific Mails Meeting Materials for Annual General and Special Meeting in Connection with Previously Announced Plan of Arrangement with ICG Silver & Gold Ltd.
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
